<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34404845</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Extensive phenotypic characterisation of a human TDP-43<sup>Q331K</sup>&#xa0;transgenic mouse model of amyotrophic lateral sclerosis (ALS).</ArticleTitle><Pagination><StartPage>16659</StartPage><MedlinePgn>16659</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16659</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-96122-z</ELocationID><Abstract><AbstractText>The majority of preclinical studies in ALS have relied on transgenic models with overexpression of mutant human superoxide dismutase 1 (SOD1), widely regarded to have failed in terms of translation of therapeutic effects. However, there are still no widely accepted models of other genetic subtypes of ALS. The majority of patients show ubiquitinated cytoplasmic inclusions of TAR DNA binding protein of 43 kilodaltons (TDP-43) in spinal motor neurons at the end stage of disease and a small proportion have mutations in TARDBP, the gene encoding TDP-43. TDP-43 transgenic mouse models have been produced, but have not been widely adopted. Here, we characterised one of these models available from the Jackson Laboratory in detail. Compared to TDP-43<sup>WT</sup> mice, TDP-43<sup>Q331K</sup> mice had 43% less hindlimb muscle mass at 6&#xa0;months and a 73% reduction in hindlimb compound muscle action potential at 8&#xa0;months of age. Rotarod and gait analysis indicated motor system decline with elevated weight gain. At the molecular level, the lack of TDP-43 cellular pathology was confirmed with a surprising increase in nuclear TDP-43 in motor neurons. Power analysis indicated group sizes of 12-14 mice&#xa0;are needed to detect 10-20% changes in measured parameters with a power of 80%, providing valid readouts for preclinical testing. Overall, this model may represent a useful component of multi-model pre-clinical therapeutic studies for ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Jodie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alix</LastName><ForeName>James J P</ForeName><Initials>JJP</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK. r.j.mead@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K015273/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34404845</ArticleId><ArticleId IdType="pmc">PMC8370970</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-96122-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-96122-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller BA, et al. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol. 2012;124:733&#x2013;747. doi: 10.1007/s00401-012-1035-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1035-z</ArticleId><ArticleId IdType="pubmed">22941224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J, Amor S. Modelling amyotrophic lateral sclerosis in mice. Drug Discov. Today Dis. Model. 2017;25&#x2013;26:35&#x2013;44. doi: 10.1016/j.ddmod.2018.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddmod.2018.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X, Chiang PM, Price DL, Wong PC. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. USA. 2010;107:16325&#x2013;16330. doi: 10.1073/pnas.1003459107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1003459107</ArticleId><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010;30:10851&#x2013;10859. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011;6:73. doi: 10.1186/1750-1326-6-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-73</ArticleId><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136:1371&#x2013;1382. doi: 10.1093/brain/awt029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt029</ArticleId><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J. Biol. Chem. 2012;287:27335&#x2013;27344. doi: 10.1074/jbc.M112.359000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.359000</ArticleId><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int. J. Exp. Pathol. 2013;94:56&#x2013;64. doi: 10.1111/iep.12006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2013;1584:59&#x2013;72. doi: 10.1016/j.brainres.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.10.013</ArticleId><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S, et al. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol. Neurodegener. 2014;9:24. doi: 10.1186/1750-1326-9-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-24</ArticleId><ArticleId IdType="pmc">PMC4088917</ArticleId><ArticleId IdType="pubmed">24938805</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA. 2013;110:E736&#x2013;745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Stover KR, Campbell MA, Van Winssen CM, Brown RE. Analysis of motor function in 6-month-old male and female 3xTg-AD mice. Behav. Brain Res. 2015;281:16&#x2013;23. doi: 10.1016/j.bbr.2014.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.11.046</ArticleId><ArticleId IdType="pubmed">25486177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang PM, et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc. Natl. Acad. Sci. USA. 2010;107:16320&#x2013;16324. doi: 10.1073/pnas.1002176107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002176107</ArticleId><ArticleId IdType="pmc">PMC2941284</ArticleId><ArticleId IdType="pubmed">20660762</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, et al. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS ONE. 2013;8:7e71793. doi: 10.1371/journal.pone.0071793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071793</ArticleId><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, et al. Optimised and rapid pre-clinical screening in the SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS) PLoS ONE. 2011;6:e23244. doi: 10.1371/journal.pone.0023244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023244</ArticleId><ArticleId IdType="pmc">PMC3158065</ArticleId><ArticleId IdType="pubmed">21876739</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. FTD and ALS-translating mouse studies into clinical trials. Nat Rev Neurol. 2015;11:360&#x2013;366. doi: 10.1038/nrneurol.2015.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.65</ArticleId><ArticleId IdType="pubmed">25939274</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricketts T, et al. A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects. PLoS ONE. 2014;9:e85962. doi: 10.1371/journal.pone.0085962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0085962</ArticleId><ArticleId IdType="pmc">PMC3897576</ArticleId><ArticleId IdType="pubmed">24465814</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, et al. HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res. 2012;1460:88&#x2013;95. doi: 10.1016/j.brainres.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.04.003</ArticleId><ArticleId IdType="pubmed">22578468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol. Commun. 2015;3:36. doi: 10.1186/s40478-015-0212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol. Neurodegener. 2012;7:27. doi: 10.1186/1750-1326-7-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-27</ArticleId><ArticleId IdType="pmc">PMC3419078</ArticleId><ArticleId IdType="pubmed">22697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol. 2016;15:332&#x2013;342. doi: 10.1016/S1474-4422(15)00380-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00380-4</ArticleId><ArticleId IdType="pubmed">26822748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Body mass index delineates ALS from FTD: implications for metabolic health. J. Neurol. 2014;261:1774&#x2013;1780. doi: 10.1007/s00415-014-7416-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7416-6</ArticleId><ArticleId IdType="pubmed">24957296</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve. 2016;53:169&#x2013;182. doi: 10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CJ, et al. Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res. 2011;1394:90&#x2013;104. doi: 10.1016/j.brainres.2011.02.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.02.060</ArticleId><ArticleId IdType="pubmed">21354109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Santos-Nogueira E, Osta R, Navarro X. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol. 2011;122:1660&#x2013;1670. doi: 10.1016/j.clinph.2011.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.01.045</ArticleId><ArticleId IdType="pubmed">21354365</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol. Commun. 2019;7:166. doi: 10.1186/s40478-019-0800-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0800-9</ArticleId><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson, J. Beyond SOD1: Detailed Characterisation of a TDP-43 Transgenic Mouse Model of Motor Neurone Disease PhD thesis, University of Sheffield (2017).</Citation></Reference><Reference><Citation>Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000412</ArticleId><ArticleId IdType="pmc">PMC2893951</ArticleId><ArticleId IdType="pubmed">20613859</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 2007;39:175&#x2013;191. doi: 10.3758/BF03193146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BF03193146</ArticleId><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>